Harnessing the power of the human immune system to understand and design precision immune medicines.
Our Science Decoding with purpose, deploying with precision.
While the immune system is the most complex and fine-tuned internal ‘medicine-producing’ engine ever created, harnessing its power to prevent and treat disease remains a new frontier. The key to the next generation of immune medicines lies in understanding the inner workings of the immune synapse – the interaction between T cells and antigen presenting cells – and an individual’s associated T cell “repertoire.”
Through its deep understanding of cellular immunity, Repertoire is designing a new class of precision immune medicines based on a novel strategy:
- Decoding with purpose. Learning the language of our immune codes to detect and isolate relevant T cells based on their reactivity and specificity to disease-causing antigens.
- Deploying with precision. Using this knowledge to design novel immune medicines for different kinds of cancer, autoimmune disorders and infectious diseases.
Unlocking the power of immune codes to create precision immune medicines
Fully integrated immune discovery and therapeutics
- Proprietary Antigen and TCR Discovery Technologies
- Advanced T Cell Clonotype Analytics
- Proven T Cell, Protein, and Nano Development & Proprietary GMP Manufacturing
- Translational Medicine Expertise and Iterative Clinical Trials
Repertoire Immune Medicines to Present at the Citi 15th Annual BioPharma Virtual Conference
Repertoire Immune Medicines Receives Funding From COVID-19 High Performance Computing Consortium
Publications & Presentations
Deep TLR Primed™ T cells induce potent anti-tumor activity without systemic toxicity.
Combining Deep IL-12 Primed™ and Deep IL-15 Primed™ T cells induces potent antigen-dependent in vitro cytotoxicity and in vivo anti-tumor activity.
Adoptive transfer of deep primed™ IL-12 T-cells increases sensitivity to PD-L1 blockade for superior efficacy in checkpoint refractory tumors.
At Repertoire, our goal is simple – harness the intrinsic ability of the immune synapse to prevent and cure disease. This mission is a challenging one, requiring a complex and multi-dimensional approach that integrates cutting-edge biology and sophisticated, novel technologies. We stand ready to meet this challenge with our unique platforms, our focused and proven team, and our unsurpassed network of researchers, clinicians, academics and entrepreneurs.
Board of Directors
Professors in Residence
A meaningful shift in the landscape of immune medicines requires the right people – an innovative team with the right ideas, drive and ability to execute on our shared vision. This is the team we are building at Repertoire. We are continually looking for the best and the brightest and recruit those whose own passion and ambition will contribute to fulfilling our mission.Open Positions
John Cox, M.B.A.Chief Executive Officer
John previously served as CEO of Torque Therapeutics, which combined with Cogen Immune Medicine to form Repertoire. Prior to that, Mr. Cox served as CEO of Bioverativ, leading its spin-out from Biogen in 2016 through its acquisition by Sanofi in 2018. Previously, he held several senior executive positions at Biogen from 2003 to 2016, most recently serving as Executive Vice President of Pharmaceutical Operations and Technology, with responsibility for overseeing Biogen’s global manufacturing facilities, supply chain operations, technical development, quality and engineering, and development and commercialization of Biogen’s biosimilars business. From October 2015 to May 2016, Mr. Cox also served as interim Executive Vice President, Global Therapeutic Operations, responsible for Biogen’s therapeutic groups of Specialty Medicines and Rare Diseases, which included responsibility for the global commercial performance of Biogen’s marketed products. His additional positions with Biogen included Senior Vice President of Technical Operations, Senior Vice President of Global Manufacturing, and Vice President of Manufacturing and General Manager of Biogen’s operations in Research Triangle Park, North Carolina. He earned his MBA in finance from the University of Michigan and a BS in cell biology from California State University.
Lucia CelonaEVP, Chief Human Resources Officer
Lucia comes to Repertoire Immune Medicines with an extensive background spanning more than 25 years of Human Resources expertise working within the technology and life sciences industries. She has held positions in most HR disciplines – Training & Development, Compensation & Benefits, Employee Relations, Talent Acquisition, Analytics and HR Generalist. Most recently, Ms. Celona was the Chief People Officer at Apellis Pharmaceuticals where she focused on the Company’s organizational build to commercial launch. Prior to her role at Apellis, Ms. Celona was the Chief HR and Communications Officer at Bioverativ, where she was instrumental in the formation of the company and directed matters relating to talent, organization design, culture, public affairs and employee communications. Prior to that, she worked at Biogen as the Vice President, Human Resources for Biogen’s Pharmaceutical Operations and Technology Organization. Prior to Biogen, Ms. Celona held various HR leadership positions in companies such as Hewlett Packard, Philips Medical Systems, and Sentillion. She earned her BA in Accounting from Bentley University and completed the Advanced HR Executive Program at the University of Michigan.
Anthony Coyle, Ph.D.President, Research and Development
Dr. Coyle brings to Repertoire more than 25 years of experience in drug discovery and development, spanning academia, early-stage biotechnology companies and global pharmaceutical organizations. Most recently, he was the Co-Founder, President and CEO of Pandion Therapeutics, a clinical-stage biotechnology company focused on developing novel bi-specific antibody therapeutics to locally modulate the immune system in a number of autoimmune disorders. Prior to Pandion, Dr. Coyle was a Senior Vice President and Chief Scientific Officer at Pfizer where he launched Pfizer’s Centers for Therapeutic Innovation (CTI), a collaborative Research and Development model between Pfizer and premier academic medical centers, patient advocacy groups and the National Institute of Health. Before Pfizer, Dr. Coyle was Vice President and Global Head of Respiratory, Inflammation, and Autoimmunity Research at Medimmune Biologics, a Division of AstraZeneca. Prior to his work at MedImmune, he held leadership positions at Millennium Pharmaceuticals and Glaxo Institute in Geneva. Earlier in his academic career, he was a postdoctoral fellow at the Institute Pasteur in Paris, National Jewish Centre for Immunology in Denver and at CIBA in Basel, Switzerland.
A graduate of King’s College, University of London, Dr. Coyle has authored more than 200 peer-reviewed publications and holds 13 issued U.S. patents and more than 30 published patent applications. He speaks globally on his research and on collaborative approaches to drug development, and he served on the Scientific Advisory Boards of Children’s Hospital Boston Technology Development Fund and the Lupus Research Alliance in New York.
Andrea DiFabio, J.D.Chief Legal and Administrative Officer
Andrea brings more than two decades of legal experience within the life sciences industry—spanning M&A, commercial, corporate, compliance, business development and R&D to her role at Repertoire. Previously, she served as Chief Legal Officer and Corporate Secretary at Codiak BioSciences Inc. Prior to that, Ms. DiFabio served as the Chief Legal Officer at Bioverativ where she was instrumental in the formation of the company through its acquisition by Sanofi and directed matters relating to corporate governance and strategy, intellectual property and business development. She was previously Chief Research and Business Development Counsel at Biogen and prior to that, Corporate Vice President and Deputy General Counsel at Parexel International, a global contract research organization, based in Waltham, MA. Ms. DiFabio also has prior experience as a trial lawyer for two Boston law firms, Brown Rudnick Freed & Gesmer, and Robins, Kaplan Miller & Ceresi, where she focused on business litigation. She earned a JD from Northeastern University School of Law and a BA from Boston University, where she also participated in the Executive “Mini-MBA” Program.
Tim Harris, Ph.D.EVP, Corporate Development
Dr. Harris is a science and business leader with more than 40 years of experience guiding and leading laboratory work and scientists in a range of molecular research areas. He was most recently the Executive Vice President of Research and Development at Bioverativ, where he led the company’s scientific strategy, advancing pipeline programs and optimizing research and development operations. Dr. Harris was a venture partner at SV Life Sciences, where he helped to identify and analyze investment opportunities for its two newest funds. From 2011 to 2016, he held the roles of Senior Vice President, Precision Medicine and Senior Vice President, Translational Medicine and Biochemistry at Biogen, where he established foundational innovative technologies that advanced R&D efforts. Dr. Harris served in numerous leadership roles with a variety of small and large biotech and pharmaceutical companies and began his scientific career working on animal viruses, such as foot & mouth disease, and was one of the first molecular biologists (1981) at the UK Biotech company Celltech (now UCB Pharma). Dr. Harris currently serves as a visiting Professor at Columbia University and earned his BSc, Ph.D., Dsc from the University of Birmingham England.
Sok Cheng Soh, M.B.A.Chief Financial Officer
Sok has more than25 years of experience in finance and public accounting, including treasury, controllership, operations, and financial planning. Ms. Soh was previously Chief Financial Officer of Torque Therapeutics, which combined with Cogen Immune Medicine to form Repertoire. Prior to joining Torque, she was Vice President of Treasury and Tax at Bioverativ, a biotechnology company acquired in 2018 by Sanofi, where she established and built the company’s tax and treasury capabilities. Previously, she was Assistant Treasurer at Boston Scientific, where she led capital market initiatives, financial risk management, and treasury operations. Before joining Boston Scientific in 2011, she held positions of increasing responsibility at United Technologies where her experience included a variety of global finance roles. Ms. Soh received an MBA from the University of Chicago Booth School of Business and a BA in accounting from the University of Singapore.
Jan Kisielow, Ph.D.Chief Scientific Officer, Tepthera
Jan has over 20 years of academic experience in molecular immunology and is the Chief Scientific Officer of Tepthera Ltd., a subsidiary of Repertoire Immune Medicine. He co-founded Tepthera Ltd. as a spin-off from the Institute for Molecular Health Science at the ETH Zurich, where he created platform technologies allowing for the efficient identification of the antigenic reactivity of T cells to provide the basis for personalised immunotherapies. He earned his Ph.D. in cell biology from the Basel Institute for Immunology, University of Basel.
Franz-Josef Obermair, Ph.D.General Manager, Tepthera
Bio coming soon.
Daniel Pregibon, Ph.D.Head of Platform Discovery and Technology
Dr. Pregibon brings to Repertoire more than 15 years of experience developing and commercializing platforms. Previously, he served as SVP, Head of Platform at Cogen Immune Medicine, which was merged with Torque Therapeutics to form Repertoire. Prior to joining Cogen, Dr. Pregibon co-founded Firefly BioWorks, where he served as President and Chief Technology Officer from inception through the company’s acquisition by Abcam in 2015. In this capacity, he led the ideation and productization of the FirePlex Platform used for the direct, highly-multiplexed quantification of microRNAs and cytokines in biofluids. He earned his Ph.D. from the Department of Chemical Engineering at the Massachusetts Institute of Technology.
Mojca Skoberne, Ph.D.Head of Immunology and Early Development
Dr. Skoberne brings over 15 years of experience in immunology and therapeutics development to her role at Repertoire. Previously, she served as SVP, Immunology Research and Early Development of Cogen Immune Medicine, which combined with Torque Therapeutics to form Repertoire. Prior to joining Cogen, Dr. Skoberne served as Vice President of Immunology at Gritstone Oncology and prior to that as Director and Program Leader at Genocea Biosciences. At her previous positions she was responsible for discovery and development of programs in cancer and infectious diseases, respectively. She earned her Ph.D. from University of Ljubljana.